International Journal of Hypertension systemic hypertension and osteoarthritis,” American Journal of Cardiology, vol. 90, no. 9, pp. 959–963, 2002. [37] G. A. Cinotti and F. Pugliese, “Prostaglandins in blood pressure regulation,” Kidney International, vol. 34, no. 25, pp. S57–S60, 1988. [38] G. A. FitzGerald, “COX-2 and beyond: approaches to prostaglandin inhibition in human disease,” Nature Reviews Drug Discovery, vol. 2, no. 11, pp. 879–890, 2003. [39] A. Whelton, G. Schulman, C. Wallemark et al., “Eﬀects of celecoxib and naproxen on renal function in the elderly,” Archives of Internal Medicine, vol. 160, no. 10, pp. 1465–1470, 2000. [40] F. Catella-Lawson, B. Mcadam, B. W. Morrison et al., “Eﬀects of speciﬁc inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids,” Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 2, pp. 735–741, 1999. [41] C. Patrono and M. J. Dunn, “The clinical signiﬁcance of inhi- bition of renal prostaglandin synthesis,” Kidney International, vol. 32, no. 1, pp. 1–12, 1987. [42] J. Rossat, M. Maillard, J. Nussberger, H. R. Brunner, and M. Burnier, “Renal eﬀects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects,” Clinical Pharmacology and Therapeutics, vol. 66, no. 1, pp. 76–84, 1999. [43] A. G. Johnson, T. V. Nguyen, R. Owe-Young, D. J. Williamson, and R. O. Day, “Potential mechanisms by which nonsteroidal anti-inﬂammatory drugs elevate blood pressure: the role of endothelin-1,” Journal of Human Hyper- tension, vol. 10, no. 4, pp. 257–261, 1996. [44] L. S. Lohmander, D. McKeith, O. Svensson et al., “A randomised, placebo controlled, comparative trial of the gas- trointestinal safety and eﬃcacy of AZD3582 versus naproxen in osteoarthritis,” Annals of the Rheumatic Diseases, vol. 64, no. 3, pp. 449–456, 2005. [45] T. J. Schnitzer, A. J. Kivitz, R. S. Lipetz, N. Sanders, and A. Hee, “Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee,” Arthritis & Rheumatism, vol. 53, no. 6, pp. 827–837, 2005. [46] C. Naproxcinod Baerwald, P. Verdecchia, B. Duquesroix, H. Frayssinet, and T. Ferreira, “Eﬃcacy, safety and eﬀects on BP of Naproxcinod 750 Mg bid compared with Placebo and Naproxen 500 Mg bid in patients with osteoarthritis of the hip,” Arthritis & Rheumatism, vol. 62, no. 12, pp. 3635–3644, 2010. [47] T. J. Schnitzer, M. C. Hochberg, C. E. Marrero, B. Duques- roix, H. Frayssinet, and M. Beekman, “Eﬃcacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53- week prospective randomized multicenter study,” Seminars in Arthritis and Rheumatism, vol. 40, no. 4, pp. 285–297, 2011. [48] R. L. Prentice, “On the ability of blood pressure eﬀects to explain the relation between oral contraceptives and cardiovascular disease,” American Journal of Epidemiology, vol. 127, no. 2, pp. 213–219, 1988. [49] T. Rosenthal and S. Oparil, “Oral contraceptives, hormones replacement therapy, and hypertension,” in Comprehensive Hypertension, G. Lip and J. Hall, Eds., Elsevier/Mosby, New York, NY, USA, 2007. [50] L. Chasan-Taber, W. C. Willett, J. E. Manson et al., “Prospec- tive study of oral contraceptives and hypertension among women in the United States,” Circulation, vol. 94, no. 3, pp. 483–489, 1996. 11 [51] J. N. Lubianca, C. S. Faccin, and F. D. Fuchs, “Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women,” Contraception, vol. 67, no. 1, pp. 19–24, 2003. [52] W. B. White, V. Hanes, V. Chauhan, and B. Pitt, “Eﬀects of a new hormone therapy, drospirenone and 17-β-estradiol, in postmenopausal women with hypertension,” Hypertension, vol. 48, no. 2, pp. 246–253, 2006. [53] World Health Organization, “Low dose combined oral contraceptives,” in Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use, WHO, Geneva, Switzerland, 3rd edition, 2004. [54] American College of Obstetricians and Gynecologists Prac- tice Bulletin, “Use of hormonal contraception in women with coexisting medical conditions: clinical management guide- lines for obstetrician-gynecologists,” Obstetrics & Gynecology, vol. 107, pp. 1453–1472, 2006. [55] N. Ferrara, K. J. Hillan, H. P. Gerber, and W. Novotny, “Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer,” Nature Reviews Drug Discovery, vol. 3, no. 5, pp. 391–400, 2004. [56] H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Beva- cizumab plus irinotecan, ﬂuorouracil, and leucovorin for metastatic colorectal cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. [57] S. Shinkaruk, M. Bayle, G. Lain, and G. Deleris, “Vascular Endothelial Cell Growth Factor (VEGF), an emerging target for cancer chemotherapy,” Current Medicinal Chemistry— Anti-Cancer Agents, vol. 3, no. 2, pp. 95–117, 2003. [58] D. A. Sica, “Angiogenesis inhibitors and hypertension: an emerging issue,” Journal of Clinical Oncology, vol. 24, no. 9, pp. 1329–1331, 2006. [59] H. M. W. Verheul and H. M. Pinedo, “Possible molecular mechanisms involved in the toxicity of angiogenesis inhibi- tion,” Nature Reviews Cancer, vol. 7, no. 6, pp. 475–485, 2007. [60] X. Zhu, S. Wu, W. L. Dahut, and C. R. Parikh, “Risks of pro- teinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 49, no. 2, pp. 186–193, 2007. [61] S. Wu, J. J. Chen, A. Kudelka, J. Lu, and X. Zhu, “Incidence and risk of hypertension with sorafenib in patients with can- cer: a systematic review and meta-analysis,” Lancet Oncology, vol. 9, no. 2, pp. 117–123, 2008. [62] X. Zhu, K. Stergiopoulos, and S. Wu, “Risk of hypertension and renal dysfunction with an angiogenesis inhibitor suni- tinib: systematic review and meta-analysis,” Acta Oncologica, vol. 48, no. 1, pp. 9–17, 2009. [63] J. P. Spano, C. Chodkiewicz, J. Maurel et al., “Eﬃcacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study,” Lancet, vol. 371, no. 9630, pp. 2101–2108, 2008. [64] G. Friberg, K. Kasza, E. E. Vokes, and H. L. Kindler, “Early hypertension as a potential pharmacodynamic marker for survival in pancreatic cancer patients treated with beva- cizumab and gemcitabine,” Journal of Clinical Oncology, vol. 23, no. 16S, part I, article 3020, 2005. [65] B. P. Schneider, M. Wang, M. Radovich et al., “Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with out- come in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100,” Jour- nal of Clinical Oncology, vol. 26, no. 28, pp. 4672–4678, 2008.